Antigen choice in adoptive T-cell therapy of cancer

Current Opinion in Immunology

Volumn 21, Issue 2, 2009, Pages 190-199

  Offringa, Rienk ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; MUCIN 1; PLASMID VECTOR; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; DONOR LYMPHOCYTE INFUSION; EATON LAMBERT SYNDROME; GENETIC ENGINEERING; GENETIC TRANSFECTION; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NEOPLASM; NONHUMAN; ONCOGENE; PARANEOPLASTIC SYNDROME; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIGENS, NEOPLASM; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 65249156479     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2009.02.006     Document Type: Review

References (85)

1. Bowen D.G., and Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 (2005) 946-952
2. Zajac A.J., Murali-Krishna K., Blattman J.N., and Ahmed R. Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. Curr Opin Immunol 10 (1998) 444-449
3. Locker G.Y., Hamilton S., Harris J., Jessup J.M., Kemeny N., Macdonald J.S., Somerfield M.R., Hayes D.F., and Bast Jr. R.C. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24 (2006) 5313-5327
4. Miller R.A., Lowder J.N., Gralow J., Meeker T., and Levy R. In vitro tests that predict tumor-associated idiotype levels in the serum of patients with B cell lymphomas and leukemias. Blood 69 (1987) 1249-1254. Serum levels of idiotype Ig are primarily found in plasma cell-related cancers such as multiple myeloma.
5. Arlen P.M., Gulley J.L., Madan R.A., Hodge J.W., and Schlom J. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol 27 (2007) 451-462
6. Kanter G., Yang J., Voloshin A., Levy S., Swartz J.R., and Levy R. Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. Blood 109 (2007) 3393-3399. Typically, transplantable tumor models do not recapitulate the chronic aspect of cancer and therefore not the chronic exposure of the host immune system to tumor-associated antigens.
7. ••], very low levels of thymic expression can already suffice to induce antigen-specific central tolerance.
8. •]) must be taken into account with respect to the design of cancer vaccines.
9. Kolb H.J., Mittermuller J., Clemm C., Holler E., Ledderose G., Brehm G., Heim M., and Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76 (1990) 2462-2465
10. Hambach L., and Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol 17 (2005) 202-210
11. Griffioen M., van Egmond H.M., Barnby-Porritt H., van der Hoorn M.A., Hagedoorn R.S., Kester M.G., Schwabe N., Willemze R., Falkenburg J.H., and Heemskerk M.H. Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application. Haematologica 93 (2008) 1535-1543
12. Carbone D.P., Ciernik I.F., Kelley M.J., Smith M.C., Nadaf S., Kavanaugh D., Maher V.E., Stipanov M., Contois D., Johnson B.E., et al. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol 23 (2005) 5099-5107
13. Kessler J.H., Bres-Vloemans S.A., van Veelen P.A., de Ru A., Huijbers I.J., Camps M., Mulder A., Offringa R., Drijfhout J.W., Leeksma O.C., et al. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes. Leukemia 20 (2006) 1738-1750
14. Khleif S.N., Abrams S.I., Hamilton J.M., Bergmann-Leitner E., Chen A., Bastian A., Bernstein S., Chung Y., Allegra C.J., and Schlom J. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother 22 (1999) 155-165
15. Yanuck M., Carbone D.P., Pendleton C.D., Tsukui T., Winter S.F., Minna J.D., and Berzofsky J.A. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res 53 (1993) 3257-3261
16. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
17. Segal N.H., Parsons D.W., Peggs K.S., Velculescu V., Kinzler K.W., Vogelstein B., and Allison J.P. Epitope landscape in breast and colorectal cancer. Cancer Res 68 (2008) 889-892
18. Forrest W.F., and Cavet G. Comment on "The consensus coding sequences of human breast and colorectal cancers". Science 317 (2007) 1500 [author reply 1500]
19. Getz G., Hofling H., Mesirov J.P., Golub T.R., Meyerson M., Tibshirani R., and Lander E.S. Comment on "The consensus coding sequences of human breast and colorectal cancers". Science 317 (2007) 1500
20. Rubin A.F., and Green P. Comment on "The consensus coding sequences of human breast and colorectal cancers". Science 317 (2007) 1500
21. Linnebacher M., Gebert J., Rudy W., Woerner S., Yuan Y.P., Bork P., and von Knebel Doeberitz M. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer 93 (2001) 6-11
22. Saeterdal I., Bjorheim J., Lislerud K., Gjertsen M.K., Bukholm I.K., Olsen O.C., Nesland J.M., Eriksen J.A., Moller M., Lindblom A., et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 98 (2001) 13255-13260
23. Speetjens F.M., Lauwen M.M., Franken K.L., Janssen-van Rhijn C.M., van Duikeren S., Bres S.A., van de Velde C.J., Melief C.J., Kuppen P.J., van der Burg S.H., et al. Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer. Int J Cancer 123 (2008) 838-845. This study constitutes a first attempt to investigate the intracellular behavior of proteins encoded by frameshift mutated genes commonly found in MSI+ cancers. As shown in Refs. [24,25], only accumulating antigens are expected to be cross-presented by dendritic cells. Antigen-specific help of tumor-specific CD4+ T-cells can, in the context of solid tumors, only be effective if tumor antigens are cross-presented by DCs in the tumor microenvironment and draining lymphoid tissues. In view of the notion that MSI+ cancers frequently display impairments in MHC class I antigen presentation, the use of MHC class II-restricted TCRs is recommended to counter immune escape.
24. Norbury C.C., Basta S., Donohue K.B., Tscharke D.C., Princiotta M.F., Berglund P., Gibbs J., Bennink J.R., and Yewdell J.W. CD8+ T cell cross-priming via transfer of proteasome substrates. Science 304 (2004) 1318-1321
25. Wolkers M.C., Brouwenstijn N., Bakker A.H., Toebes M., and Schumacher T.N. Antigen bias in T cell cross-priming. Science 304 (2004) 1314-1317
26. Bowne W.B., Srinivasan R., Wolchok J.D., Hawkins W.G., Blachere N.E., Dyall R., Lewis J.J., and Houghton A.N. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 190 (1999) 1717-1722
27. Cohen A.D., Diab A., Perales M.A., Wolchok J.D., Rizzuto G., Merghoub T., Huggins D., Liu C., Turk M.J., Restifo N.P., et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res 66 (2006) 4904-4912
28. Overwijk W.W., Lee D.S., Surman D.R., Irvine K.R., Touloukian C.E., Chan C.C., Carroll M.W., Moss B., Rosenberg S.A., and Restifo N.P. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A 96 (1999) 2982-2987
29. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., Toes R.E., Offringa R., and Melief C.J. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194 (2001) 823-832
30. Weber L.W., Bowne W.B., Wolchok J.D., Srinivasan R., Qin J., Moroi Y., Clynes R., Song P., Lewis J.J., and Houghton A.N. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 102 (1998) 1258-1264
31. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
32. Uchi H., Stan R., Turk M.J., Engelhorn M.E., Rizzuto G.A., Goldberg S.M., Wolchok J.D., and Houghton A.N. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol 90 (2006) 215-241
33. Muranski P., Boni A., Antony P.A., Cassard L., Irvine K.R., Kaiser A., Paulos C.M., Palmer D.C., Touloukian C.E., Ptak K., et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112 (2008) 362-373. The trp1-specific TCR used in this study was isolated from trp-1 ko mice.
34. Overwijk W.W., Theoret M.R., Finkelstein S.E., Surman D.R., de Jong L.A., Vyth-Dreese F.A., Dellemijn T.A., Antony P.A., Spiess P.J., Palmer D.C., et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198 (2003) 569-580. The first study in which TCR-transgenic T-cells targeting a natural tumor antigen were used for adoptive transfer experiments. All prior studies made use of TCR-transgenic T-cells targeting engineered auto-antigens, such as the OT-1/ovalbumin combination. The gp100-specific TCR was isolated from wild type, gp100-expressing mice. The poor binding of the murine gp100 epitope to MHC class I offers the most plausible explanation for escape of this high affinity TCR from thymic deletion, in spite of reported expression of gp100 by mTEC.
35. Acres B., and Limacher J.M. MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines 4 (2005) 493-502
36. •,58].
37. Maker A.V., Yang J.C., Sherry R.M., Topalian S.L., Kammula U.S., Royal R.E., Hughes M., Yellin M.J., Haworth L.R., Levy C., et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 29 (2006) 455-463
38. Reddy P., and Ferrara J.L. Immunobiology of acute graft-versus-host disease. Blood Rev 17 (2003) 187-194
39. Ward P.L., Koeppen H., Hurteau T., and Schreiber H. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med 170 (1989) 217-232
40. Yang J.C., and Perry-Lalley D. The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors. J Immunother 23 (2000) 177-183
41. van Hall T., van de Rhee N.E., Schoenberger S.P., Vierboom M.P., Verreck F.A., Melief C.J., and Offringa R. Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes. Cancer Res 58 (1998) 3087-3093
42. Kudo-Saito C., Schlom J., and Hodge J.W. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res 11 (2005) 2416-2426. This paper concludes a long stretch of papers suggesting that CEA-specific T-cell responses can be instrumental in selective eradication of CEA-overexpressing tumors in CEA-transgenic mice, and is the first one to acknowledge a role of T-cell responses against non-self-antigens. The authors propose that the CD8+ T-cell response against the retroviral antigen (the same as found described in Ref. [48]) is a result of antigen-spreading, due to killing of tumor cells by the CEA-specific response. More likely, the response against the retroviral antigen was primed as a result of tumor cell injection. Shortly after injection of transplantable tumor cells, many of these cells die. As such, they constitute a tumor cell vaccine that can result in, albeit inefficient, T-cell priming.
43. Facciabene A., Aurisicchio L., Elia L., Palombo F., Mennuni C., Ciliberto G., and La Monica N. DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection. Hum Gene Ther 17 (2006) 81-92
44. Ojima T., Iwahashi M., Nakamura M., Matsuda K., Nakamori M., Ueda K., Naka T., Ishida K., Primus F.J., and Yamaue H. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice. Int J Cancer 120 (2007) 585-593
45. Clarke P., Mann J., Simpson J.F., Rickard-Dickson K., and Primus F.J. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res 58 (1998) 1469-1477
46. Bos R., van Duikeren S., van Hall T., Kaaijk P., Taubert R., Kyewski B., Klein L., Melief C.J., and Offringa R. Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire. Cancer Res 65 (2005) 6443-6449. Importantly, CEA-expression in the thymi of CEA-transgenic mice is mirrored by expression of this gene in human thymi, suggesting that the human CEA-specific T-cell repertoire is similarly blunted by central tolerance.
47. Cloosen S., Arnold J., Thio M., Bos G.M., Kyewski B., and Germeraad W.T. Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy. Cancer Res 67 (2007) 3919-3926. This paper confirms that CEA is expressed in the human thymus. Furthermore, authors propose that, due to expression of highly glycosylated MUC1 in thymus, T-cell precursors recognizing hypoglycosylated peptides that may be presented by tumor cells (see also Ref. [50]) could escape thymic deletion.
48. Bos R., van Duikeren S., Morreau H., Franken K., Schumacher T.N., Haanen J.B., van der Burg S.H., Melief C.J., and Offringa R. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res 68 (2008) 8446-8455. The first study that directly addresses the suitability of CEA for cancer targeting. The retroviral epitope against which CD8+ T-cell immunity was found in tumor-clearing CEA-transgenic mice, is the same as described in Ref. [42].
49. Vezys V., and Lefrancois L. Cutting edge: inflammatory signals drive organ-specific autoimmunity to normally cross-tolerizing endogenous antigen. J Immunol 169 (2002) 6677-6680
50. Vlad A.M., Muller S., Cudic M., Paulsen H., Otvos Jr. L., Hanisch F.G., and Finn O.J. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 196 (2002) 1435-1446
51. Turner M.S., Cohen P.A., and Finn O.J. Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J Immunol 178 (2007) 2787-2793. This paper shows that adoptive transfer of MUC1-specific T-cells does not result in toxicity. The quintessential experiment lacking from this paper is one that demonstrates tumor clearance by the adoptively transferred MUC1-specific T-cells.
52. Theobald M., and Offringa R. Anti-p53-directed immunotherapy of malignant disease. Expert Rev Mol Med 5 (2003) 1-13
53. Lauwen M.M., Zwaveling S., de Quartel L., Ferreira Mota S.C., Grashorn J.A., Melief C.J., van der Burg S.H., and Offringa R. Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen. Cancer Res 68 (2008) 893-900
54. Vierboom M.P., Nijman H.W., Offringa R., van der Voort E.I., van Hall T., van den Broek L., Fleuren G.J., Kenemans P., Kast W.M., and Melief C.J. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 186 (1997) 695-704
55. Lauwen MM, Melief CJ, Van der Burg SH, Offringa R: Manuscript in preparation.
56. Hinrichs C.S., Gattinoni L., and Restifo N.P. Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol 18 (2006) 363-370
57. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006) 126-129. A pioneering study that, even though not perfect in design, demonstrated the feasibility of TCR gene therapy in human cancer patients. Two striking aspect of this study are the following. First, in vivo persistence of adoptively transferred T-cells appears much better if ex vivo expansion phase is kept as short as possible, in line with similar findings in mouse models. Secondly, the two patients showing objective regression were not reported to display any treatment-related signs of auto-immune skin depigmentation. This would be expected if infused T-cells were highly reactive against the MART-1 antigen. The lack of depigmentation is in line with the notion that the MART-1-specific TCR used was of limited affinity (see Ref. [84]).
58. Heukamp L.C., van Hall T., Ossendorp F., Burchell J.M., Melief C.J., Taylor-Papadimitriou J., and Offringa R. Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope. J Immunother 25 (2002) 46-56
59. Vierboom M.P., Zwaveling S., Bos G.M.J., Ooms M., Krietemeijer G.M., Melief C.J., and Offringa R. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Cancer Res 60 (2000) 5508-5513. This study demonstrates that p53 turnover, rather than accumulation, is a key determinant in recognition by p53-specific CTLs.
60. Theoret M.R., Cohen C.J., Nahvi A.V., Ngo L.T., Suri K.B., Powell D.J., Dudley M.E., Morgan R.A., and Rosenberg S.A. Relationship of p53 overexpression on cancers and recognition by anti-p53 TCR transduced T cells. Hum Gene Ther 19 (2008) 1219-1231
61. Darnell R.B., and Posner J.B. Paraneoplastic syndromes affecting the nervous system. Semin Oncol 33 (2006) 270-298
62. Santomasso B.D., Roberts W.K., Thomas A., Williams T., Blachere N.E., Dudley M.E., Houghton A.N., Posner J.B., and Darnell R.B. A T-cell receptor associated with naturally occurring human tumor immunity. Proc Natl Acad Sci U S A 104 (2007) 19073-19078. As a conclusion of this paper, the authors propose to exploit the isolated HLA-A2+-restricted TCR against cdr2 for TCR gene therapy, which is surprising in view of the consequences of CDR2-specific immunity as observed in patients with paraneoplastic cerebellar degeneration.
63. Luger D., Silver P.B., Tang J., Cua D., Chen Z., Iwakura Y., Bowman E.P., Sgambellone N.M., Chan C.C., and Caspi R.R. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 205 (2008) 799-810
64. Palmer D.C., Chan C.C., Gattinoni L., Wrzesinski C., Paulos C.M., Hinrichs C.S., Powell Jr. D.J., Klebanoff C.A., Finkelstein S.E., Fariss R.N., et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A 105 (2008) 8061-8066
65. Scanlan M.J., Simpson A.J., and Old L.J. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4 (2004) 1
66. de Witte M.A., Bendle G.M., van den Boom M.D., Coccoris M., Schell T.D., Tevethia S.S., van Tinteren H., Mesman E.M., Song J.Y., and Schumacher T.N. TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol 181 (2008) 2563-2571. Preclinical proof of concept study demonstrating the efficacy and safety of cancer targeting through an - albeit engineered - prostate-specific antigen.
67. Harada M., Noguchi M., and Itoh K. Target molecules in specific immunotherapy against prostate cancer. Int J Clin Oncol 8 (2003) 193-199
68. Hassan R., Bera T., and Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 10 (2004) 3937-3942
69. Thomas A.M., Santarsiero L.M., Lutz E.R., Armstrong T.D., Chen Y.C., Huang L.Q., Laheru D.A., Goggins M., Hruban R.H., and Jaffee E.M. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 200 (2004) 297-306
70. Mutsaers S.E. The mesothelial cell. Int J Biochem Cell Biol 36 (2004) 9-16
71. Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 57 (2008) 1719-1726
72. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., and Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188 (1998) 2357-2368
73. Ossendorp F., Mengede E., Camps M., Filius R., and Melief C.J. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187 (1998) 693-702
74. Rolla S., Nicolo C., Malinarich S., Orsini M., Forni G., Cavallo F., and Ria F. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 177 (2006) 7626-7633
75. van Hall T., Wolpert E.Z., van Veelen P., Laban S., van der Veer M., Roseboom M., Bres S., Grufman P., de Ru A., Meiring H., et al. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 12 (2006) 417-424. Also in this study, CTL-mediated clearance of tumor in the absence of auto-immune toxicity was demonstrated through infusion of an ex vivo expanded clonal CTL line. In view of differences observed between such CTL clones and primary TCR-transgenic T-cells bearing the same receptor, definite proof of safety of the epitopes concerned requires repeat of this experiment with freshly isolated TCR-transgenic CD8+ T-cells.
76. Zhang B., Karrison T., Rowley D.A., and Schreiber H. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 118 (2008) 1398-1404
77. Sun Y., Song M., Jager E., Schwer C., Stevanovic S., Flindt S., Karbach J., Nguyen X.D., Schadendorf D., and Cichutek K. Human CD4+ T lymphocytes recognize a vascular endothelial growth factor receptor-2-derived epitope in association with HLA-DR. Clin Cancer Res 14 (2008) 4306-4315
78. Sun Y., Stevanovic S., Song M., Schwantes A., Kirkpatrick C.J., Schadendorf D., and Cichutek K. The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes. Blood 107 (2006) 1476-1483
79. Li Y., Wang M.N., Li H., King K.D., Bassi R., Sun H., Santiago A., Hooper A.T., Bohlen P., and Hicklin D.J. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 195 (2002) 1575-1584
80. Nair S., Boczkowski D., Moeller B., Dewhirst M., Vieweg J., and Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102 (2003) 964-971
81. Niethammer A.G., Xiang R., Becker J.C., Wodrich H., Pertl U., Karsten G., Eliceiri B.P., and Reisfeld R.A. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8 (2002) 1369-1375
82. Verdeil G., Marquardt K., Surh C.D., and Sherman L.A. Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proc Natl Acad Sci U S A 105 (2008) 16683-16688
83. Wong S.B., Bos R., and Sherman L.A. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 180 (2008) 3122-3131
84. Dudley M.E., and Rosenberg S.A. Adoptive cell transfer therapy. Semin Oncol 34 (2007) 524-531. In the discussion of this paper, the authors mention that the MART-1 specific TCR used in their prior TCR gene therapy studies (Ref. [57]) was of relative low affinity, and they refer to subsequent studies aimed at isolating more optimal TCRs.
85. Kuball J., Schmitz F.W., Voss R.H., Ferreira E.A., Engel R., Guillaume P., Strand S., Romero P., Huber C., Sherman L.A., et al. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 22 (2005) 117-129